Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Assets (2016 - 2025)

Coherus Oncology's Return on Assets history spans 12 years, with the latest figure at 0.91% for Q4 2025.

  • For Q4 2025, Return on Assets rose 39.0% year-over-year to 0.91%; the TTM value through Dec 2025 reached 0.91%, up 39.0%, while the annual FY2025 figure was 0.99%, 54.0% up from the prior year.
  • Return on Assets for Q4 2025 was 0.91% at Coherus Oncology, up from 0.71% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.91% in Q4 2025 and bottomed at 0.61% in Q1 2023.
  • The 5-year median for Return on Assets is 0.36% (2022), against an average of 0.09%.
  • The largest annual shift saw Return on Assets tumbled -58bps in 2021 before it surged 90bps in 2024.
  • A 5-year view of Return on Assets shows it stood at 0.4% in 2021, then tumbled by -40bps to 0.57% in 2022, then surged by 31bps to 0.39% in 2023, then surged by 230bps to 0.51% in 2024, then surged by 77bps to 0.91% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Return on Assets are 0.91% (Q4 2025), 0.71% (Q3 2025), and 0.9% (Q2 2025).